IBB Ventures

IBB Ventures regularly leads or co-leads seed rounds up to €1.5 million and can participate in later rounds up to a €4 million total exposure per company. It frequently acts as the first institutional investor alongside business angels in pre-seed and seed-stage financings, and while it will follow syndicates, it maintains its own due diligence and board representation rather than passively indexing alongside lead investors.

IBB Ventures does not publish a formal exclusion list, but its mandate and public sponsorship create implicit boundaries. It does not invest in defense, weapons, gambling, or businesses that contravene the statutory purpose of the ERDF. The firm also cannot invest in life sciences companies requiring clinical-trial capital beyond its ticket-size limits, which has historically tilted the portfolio toward software and light industrial tech rather than capital-intensive biotech.

IBB Ventures is capitalized through the state budget of Berlin and matching funds from the European Regional Development Fund, which makes its LP base entirely public. The firm does not have private limited partners pressing for distributions on a traditional 10-year fund cycle, but Berlin's Senate periodically reviews the mandate for renewal. This structure can create a longer holding period than a private VC fund, though the firm has executed trade sales to acquirers including AppLovin for portfolio companies such as Adjust.